Valuation: Carmat SA

Market Cap 6.15M 7.18M 5.73M 5.26M 9.89M 687M 10.08M 68.02M 26.52M 344M 26.95M 26.37M 1.14B P/E 2023
-3.09x
P/E 2024 -0.95x
Enterprise Value 59.25M 69.2M 55.28M 50.72M 95.31M 6.62B 97.19M 656M 256M 3.32B 260M 254M 10.99B EV / Sales 2023
56.1x
EV / Sales 2024 13.5x
Free-Float
89.06%
Yield 2023 *
-
Yield 2024 -
Current year 0.1
Extreme 0.099
0.1
1 year 0.08
Extreme 0.085
0.23
3 years 0.08
Extreme 0.085
9.99
5 years 0.08
Extreme 0.085
31.7
10 years 0.08
Extreme 0.085
44.95
Manager TitleAgeSince
Chief Executive Officer 55 31/08/2016
Director of Finance/CFO - 11/12/2018
Chief Tech/Sci/R&D Officer - 31/03/2025
Director TitleAgeSince
Director/Board Member 55 -
Director/Board Member 68 01/01/2017
Director/Board Member 79 19/04/2017
Date Insider Type Main position Quantity % Market Cap.
13/03/25 Sell

Chairman

1,343,333 2.3347%
13/03/25 Buy

Chairman

1,343,333 2.3347%
29/05/24 Buy

Director

1,343,333 4.6122%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-78.94%-98.60% 7.08M
-3.61%-3.93%-16.38%+17.92% 126B
-2.05%-4.06%-24.08%-1.68% 12.32B
-2.46%-2.41%+103.31%+157.51% 10.9B
+2.99%-6.01%-48.48%-68.43% 4.35B
+1.60%-1.88%-24.39%+48.84% 2.7B
-0.68%+5.27%-34.15%-71.70% 1.77B
+3.02%-0.62%-22.25%-12.11% 1.68B
+4.84%-0.01%-33.39%-34.24% 1.67B
Average +0.41%-0.86%-19.86%-6.94% 17.9B
Weighted average by Cap. -2.96%-3.50%-10.30%+22.20%

Financials

2023 2024
Net sales 3.84M 4.48M 3.58M 3.28M 6.17M 429M 6.29M 42.47M 16.56M 215M 16.83M 16.46M 711M 7.34M 8.58M 6.85M 6.29M 11.81M 821M 12.05M 81.29M 31.69M 411M 32.21M 31.51M 1.36B
Net income -53.87M -62.92M -50.26M -46.12M -86.66M -6.02B -88.37M -596M -232M -3.02B -236M -231M -9.99B -51.4M -60.03M -47.95M -44M -82.68M -5.74B -84.31M -569M -222M -2.88B -225M -220M -9.53B
Net Debt 49.64M 57.97M 46.31M 42.49M 79.85M 5.55B 81.42M 549M 214M 2.78B 218M 213M 9.2B 53.1M 62.02M 49.54M 45.46M 85.42M 5.93B 87.1M 588M 229M 2.97B 233M 228M 9.85B
Logo Carmat SA
Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.
Employees
153
  1. Stock Market
  2. Stocks
  3. ALCAR Stock